No financial details of the collaborations were released. However, Pfizer and Flagship committed $50 million each for the ...

Johnson & Johnson’s latest prospective offering to the IL-23 psoriasis space—a Protagonist Therapeutics-partnered once-daily ...

Investor confidence may be returning, with biopharma venture funding, deal value and exit activity all rising in 2024’s third ...

They need to find a bigger venue,” an attendee mutters as they pull their coat tight and brave the British rain to find one ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

Venture capital fund Jupiter Bioventures is taking off with $70 million for a portfolio of cancer-adjacent biotech startups, ...

Lindus Health has gone all-in on all-in-one CRO offerings. Less than a month after launching its All-in-One Women's Health ...

Medtronic has reported revenue gains across several of its medical device franchises, leading the company to nudge up its ...

Canadian CRO Innovaderm is looking to expand its operations across the pond with the hiring of Ina Zschocke, Ph.D., as ...

Citizen’s partnership will work with CZI’s Rare As One project, a research and funding network that includes multiple patient ...

Incyte’s $750 million Escient Pharmaceuticals buyout has rapidly run into problems. Less than six months after closing the ...

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to ...